Naropin

Surgical anaesth in epidural block for surgery (including Caesarean section), major nerve block, & field block. Acute pain management in continuous epidural infusion or intermittent bolus administration (eg, post-op or labour pain) & field block.

Adult & childn >12 yr 7.5 mg/mL Lumbar epidural anaesth Surgery: 113-188 mg (15-25 mL). Caesarean section: 113-150 mg (15-20 mL). Thoracic epidural anaesth Post-op pain relief: 38-113 mg (5-15 mL). Major nerve block (eg, brachial plexus) 75-300 mg (10-40 mL). Field block (eg, minor nerve blocks & infiltration) 7.5-225 mg (1-30 mL). 10 mg/mL Lumbar epidural anaesth Surgery: 150-200 mg (15-20 mL).

Hypersensitivity to amide-type local anaesth.

Always perform regional anaesth procedures in a properly equipped & staffed area w/ equipment & drugs necessary for monitoring & emergency resuscitation immediately available. Patients receiving major blocks should be in an optimal condition & have an IV line inserted before the blocking procedure. Avoid intravascular inj. Certain local anaesth procedures (eg, inj in the head & neck regions) may be associated w/ a higher frequency of serious adverse reactions. Patients in poor general condition due to ageing or other compromising factors (eg, partial or complete heart conduction block, advanced liver disease, or severe renal dysfunction) require special attention. Consider ECG monitoring in patients treated w/ class III antiarrhythmics (eg, amiodarone). Rare reports of cardiac arrest during use for epidural anaesth or peripheral nerve blockade. Epidural anaesth may lead to hypotension & bradycardia. Possibly porphyrinogenic & should only be prescribed to patients w/ acute porphyria where no safer alternative is available. IA continuous infusion is not an approved indication for Naropin. Avoid prolonged administration in patients treated w/ strong CYP1A2 inhibitors (eg, fluvoxamine, enoxacin). May have a very mild effect on mental function & coordination & may temporarily impair locomotion & alertness. Caution in patients w/ severe liver disease. Acidosis & reduced plasma protein conc, frequently seen in patients w/ chronic renal failure, may increase risk of systemic toxicity. Not recommended for use in childn <12 yr.

Hypotension; nausea. Paraesthesia, dizziness, headache; bradycardia, tachycardia; HTN; vomiting; urinary retention; temp elevation, rigor, back pain.

Additive systemic toxic effects w/ other local anaesth or agents structurally related to amide-type local anaesth (eg, lidocaine, mexiletine). Caution w/ class III antiarrhythmics (eg, amiodarone). Increased plasma conc w/ strong CYP1A2 inhibitors (eg, fluvoxamine, enoxacin).

Anaesthetics - Local & General

N01BB09 - ropivacaine ; Belongs to the class of amides. Used as local anesthetics.

P₁S₁S₃